Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 2, 2006 - Issue 5
Submit an article Journal homepage
4,084
Views
124
CrossRef citations to date
0
Altmetric
Review

Preclinical formulations for discovery and toxicology: physicochemical challenges

Seshadri Neervannan Director, Small Molecule Pharmaceutics, Amgen, Inc., Mail Stop 8-2-D, One Amgen Center Drive, Thousand Oaks, CA 91320, USA. [email protected]
Pages 715-731 | Published online: 03 Oct 2006

Bibliography

  • KIBBEY CE, POOLE SK, ROBINSON B, JACKSON JD, DURHAM D: An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J. Pharm. Sci (2001) 90:1164-1175.
  • LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (1997) 23(1-3):3-25.
  • LOMBARDINO JG, LOWE JA: The role of the medicinal chemist in drug discovery – then and now. Nat. Rev. Drug Discov. (2004) 3(10):853-862.
  • VENKATESH S, LIPPER RA: Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci (2000) 89(2):145-154.
  • LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods (2001) 44(1):235-249.
  • GUDMUNDSSON OS, VENKATESH S: Strategies for in silico and experimental screening of physicochemical properties. In: Biotechnology: Pharmaceutical Aspects Vol 1. Pharmaceutical profiling for drug discovery and lead selection. AAPS, Arlington, VA, USA (2004).
  • KERNS EH: High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. (2001) 90:1838-1858.
  • GARDNER CR, WALSH CT, ALMARSSON O: Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. (2004) 3(11):926-934.
  • CURATOLO W: Physical–chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today (1998) 1(9):387.
  • CALDWELL GW, RITCHIE DM, MASUCCI JA, HAGEMAN W, YAN Z: The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. (2001) 1(5):353-366.
  • BITTNER B, MOUNTFIELD RJ: Intravenous administration of poorly solule new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Dev. (2002) 5(1):59-71.
  • BITTNER B, MOUNTFIELD RJ: Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: Part I. Pharm. Ind. (2002) 64(8):800-807.
  • BITTNER B, MOUNTFIELD RJ: Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: Part II. Pharm. Ind. (2002) 64(9):985-991.
  • LEE Y, ZOCHARSKI PD, SAMAS B: An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. (2002) 253:111-119.
  • GOMEZ-ORELLANA I: Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv. (2005) 2(3):419-433.
  • SWEETANA S, AKERS MJ: Solubility principles for parenteral dosage form development. PDA J. Pharm. Sci. Technol. (1996) 50:330-342.
  • CLAASSEN V: Neglected factors in pharmacology and neuroscience research. In: Techniques in the behavioural and neural sciences. Huston JP (Ed.), Elsevier, Amsterdam, The Netherlands (1994):5-94.
  • BALLARD BE: Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J. Pharm. Sci (1968) 57(3):357-378.
  • HILLMAN RS: The subcutaneous space: a route for continuous administration of drugs? Trends Pharmacol. Sci. (1983) 4(6):245-247.
  • LANGER R: Controlled release of macromolecules. ChemTech (1982) 12(2):98-105.
  • LUKAS G, BRINDLE SD, GREENGARD P: The route of absorption of intraperitoneally administered compounds. J. Pharmacol. Exper. Ther. (1971) 178(3):562-566.
  • KRUGER S, GREVE DW, SCHUELER FW: The absorption of fluid from peritoneal cavity. Arch. Int. Pharmacodyn. Ther. (1962) 137:173-178.
  • AKIMOTO M, NAGAHATA A, FURUYA K, FUKUSHIMA S et al.: Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur. J. Pharm. Biopharm. (2000) 49:99-102.
  • DRESSMAN JB: Comparison of canine and human gastrointestinal physiology. Pharm. Res. (1986) 3:123-131.
  • MARTINEZ MN, AMIDON GL: A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. (2002) 42:620-643.
  • NEERVANNAN S: Strategies to impact solubility and dissolution rate during drug lead optimization: salt selection and prodrug design approaches. Am. Pharm. Rev. (2004) 7(5):108-113.
  • YU LX: An integrated model for determining causes of poor oral drug absorption. Pharm. Res. (1999) 16:1883-1887.
  • DIEHL K, HULL R, MORTON D, PFISTER R et al.: A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Applied Toxicol. (2001) 21:15-23.
  • HULL RM: Guideline limit volumes for dosing animals in preclinical stage of safety evaluation. Hum. Exp. Toxicol. (1995) 14:305-307.
  • CORNELIUS LM, FINCO DR, CULVER DH: Physiologic effects of rapid infusion of ringer’s lactate solution into dogs. Am. J. Vet. Res. (1978) 39:1185-1190.
  • MANN WA, KINTER LB: Characterization of maximal intravenous dose volumes in the dog (Canis Familiaris). Gen. Pharmacol. (1993) 24:357-366.
  • BARTSCH W, SPONER G, DIETMAN K, FUCHS G: Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, dietylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. Amzneimittelforschung (1976) 26:1581-1583.
  • WARD GH, YALKOWSKY SH: Studies in phlebitis VI: dilution-induced precipitation of amiodarone HCl. J. Parenteral Sci. Technol. (1993) 47:161-165.
  • ALZA CORPORATION: ALZET Osmotic Pumps, Technical Information Manual. (1992).
  • BITTNER B, THELLY TH, ISEL H, MOUNTFIELD RJ: The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. Int. J. Pharm. (2000) 205:195-198.
  • GUERRINI VH, ENGLISH PB, FILIPPICH LJ, SCHNEIDER J, BOURNE DWA: Pharmacokinetic evaluation of a slow-release cefotaxime suspension in the dog and in sheep. Am. J. Vet. Res. (1986) 47(9):2057-2061.
  • LEENARS PPAM, KOEDAM MA, WESTER PW et al.: Assessment of side-effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab. Anim. (1998) 32:387-406.
  • DARBY TD: Safety evaluation of polymer materials. Ann. Rev. Pharmacol. Toxicol. (1987) 27:157-167.
  • DUFRESNE RG: Skin necrosis from intravenously infused materials. Cutis (1987) 39:197-198.
  • BATRAKOVA EV, LI S, MILLER DW et al.: Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and caco-2 cell monolayers. Pharm. Res. (1999) 16:1366.
  • GOUGH WB, ZEILER RH, BARRECA P, EL-SHERIF N: Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J. Cardiovasc. Pharmacol. (1982) 4(3):375-380.
  • MASINI E, PLANCHENAULT J, PESSIZADI F, GAUTIER P, GAGNOL JP: Histamine-releasing properties of polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions (1985) 16(6):470-477.
  • MOUNTFIELD R, SENEPIN S, SCHLEIMER M et al.: The potential inhibitory effect of formulation ingredients on intestinal cytochrome P450. Int. J. Pharm. (2000) 211:89.
  • VAN ZUYLEN L, VERWEIJ J, SPARREBOOK A: Role of formulation vehicles in taxane pharmacology. Invest. New Drugs (2001) 19:125-141.
  • WAGNER D, SPAHN-LANGGUTH H, HANAFY A, KOGGEL A, LANGGUTH P: Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. (2001) 50(Suppl. 1):S13-S31.
  • COXON A, BOLON B, ESTRADA J, KAUFMAN S et al.: Inhibition of interleukin-1, but not tumor necrosis factor, suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. (2002) 46(10):2604-2612.
  • PETER RBN, KEITH CB, RONALD ED et al.: The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit. Toxicology (1975) 3:143-169.
  • SWANSON BN: Medical use of dimethyl sulfoxide (DMSO). Rev. Clin. Basic Pharm. (1985) 5(1-2):1-33.
  • THOME S, CRAZE J, MITCHELL C: Dimethyl sulfoxide-induced serum hyperosmolality after cryo-preserved stem cell graft. Lancet (1994) 344(8394):1431-1432.
  • LI P, ZHAO L, YALKOWSKY SH: Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J. Pharm. Sci. (1999) 88:1107-1111.
  • STELLA VJ, RAJEWSKY R: Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. (1997) 14:556.
  • CHARMAN SA, PERRY CS, CHIU, FC, MCINTOSH KA, PRANKERD RJ, CHARMAN WN: Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J. Pharm. Sci (2005) 95(2):256-267.
  • FRIJINK HW, VISSER J, HEFTING NR et al.: The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res. (1990) 8:380-384.
  • WANG YCJ, KOWAL RR: Review of excipients and pH’s for parenteral products used in the United States. J. Parenteral Drug Assoc. (1980) 34:452-462.
  • TINWALLA AY, HOESTEREY BL, XIANG T, LIM K, ANDERSON BD: Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl β-cyclodextrin. Pharm. Res. (1993) 10(8):1136-1143.
  • XIANG T, ANDERSON BD: Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin. Pharm. Res. (2002) 19(8):1215-1222.
  • JOHNSON MD, ANDERSON BD: Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci (1994) 83(8):1142-1146.
  • ERLICH L YD, PALLISTER DA, LEVINSON RS et al.: Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules. Int. J. Pharm. (1999) 179(1):49-53.
  • GAO P, MOROZOWICH W: Development of supersaturatable self-emulsifying drug delivery system formulation for improving the oral absorption of poorly soluble drugs. Expert Opin. Drug Deliv. (2006) 3(1):97-110.
  • RABINOW BE: Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. (2004) 3(9):785-796.
  • TOKUMURA T, TSUSHIMA Y, TATSUISHI K et al.: Enhancement of oral bioavailability of cinnarizine in oleic acid in beagle dogs. J. Pharm. Sci (1987) 76:286.
  • CARSTENSEN JT: Preformulation. In: Modern Pharmaceutics. Banker GS, Rhodes CT (Eds), Marcel Dekker, New York, USA (1996):213-237.
  • HAWLEY M, DOUGLAS S, MOROZOWICH W: Poster No. 2448 presented at ‘AAPS Annual Meeting’, San Francisco, CA. PharmSci (1998) 1:S-267.
  • CHARMAN SA, CHARMAN WN, ROGGE MC et al.: Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm. Res. (1992) 9:87.
  • GURSOY RN, BENITA S: Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. (2004) 58(3):173-182.
  • HUMBERSTONE A J, CHARMAN WN: Lipid-based vehicles for the oral delivery ofpoorly water-soluble drugs. Adv. Drug Deliv. Res. (1997) 25:103.
  • GUPTA P, CANNON J: Emulsion and microemulsion for drug solubilisation and delivery. In: Water Insoluble Drug Formulations. Liu R (Ed.), Interpharm Press, Denver, USA (2002).
  • CHAUMEIL J: Micronization: a method of improving the bioavailability of poorly soluble drugs. Meth. Find. Exp. Clin. Pharmacol. (1998) 20:211.
  • HÖRTER D, DRESSMAN J: Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. (1997) 25:3.
  • MÜLLER R, PETERS K: Nanosuspensions for the formulation of poorly soluble drugs, I. Preparation by a size-reduction technique. Int. J. Pharm. (1998) 160:229.
  • MÜLLER R, JACOBS C, KAYSER O: Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect from the future. Adv. Drug Deliv. Rev. (2001) 47:3.
  • MÜLLER R, PETERS K, BECKER R, KRUSS B: Nanosuspensions for the i.v. administration of poorly soluble drugs – stability during sterililzation and long-term storage. Proc. Intern. Symp. Control. Rel. Bioact. Mater. (1996) 22:574-575.
  • BLANQUET S, ZEIJDNER E, BEYSSAC E et al.: A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm. Res. (2004) 21(4):585-591.
  • KNUPP CA, SHYU WC, MORGENTHEIN EA, LEE JS, BARBHAIYA RH: Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog. Pharm. Res. (1993) 10:1157-1164.
  • ZHOU R, MOENCH P, HERAN C, XUJIN L et al.: pH-dependent dissolution of in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm. Res. (2004) 22(2):188-192.
  • CHIOU WL: Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. (2000) 17(2):135-140.
  • LUI CY, AMIDON GL, BERARDI RR, FLEISHER D, YOUNGBERG C, DRESSMAN JB: Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci (1986) 75:271-274.
  • RUBLE GR, GIARDINO OZ, FOSSCECO SL, COSMATOS D, KNAPP RJ, BARLOW NJ: The effect of commonly used vehicles on canine hematology and clinical chemistry values. J. Am. Assoc. Lab. Animal Sci. (2005) 45(1):25-29.
  • SCHULZE JDR, PETERS EE, VICKERS AW et al.: Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int. J. Pharm. (2005) 300(1-2):67-75.
  • REPPAS C, MEYER JH, SIROIS PJ, DRESSMAN JB: Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroenterology (1991) 100:1217-1223.
  • ANDERSEN FA: Final report on the safety assessment of propylene glycol and polypropylene glycols. J. Am. Coll. Toxicol. (1994) 13:437.
  • WILD SL, COSENZA ME, SULLIVAN L et al.: Comparative pathology of vehicles used for rapid in vivo screening of small molecules. Toxicologist (2001) 60(S-1):Abstract 1782.
  • RAYMOND P, PLAA GL: Effect of dosing vehicle on the hepatotoxicity of CCl4 and nephrotoxicity of CHCl3 in rats. J. Toxicol. Environ. Health (1997) 51(5):463-476.
  • GALIA E, NICOLAIDES E, HORTER D, LOBENBERG R, REPPAS C, DRESSMAN JB: Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. (1998) 15(5):698-705.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.